Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK.

Grant McCarthy Kate YoungMatthew Madin-WarburtonTyler MantaianElizabeth BrookKaylie MetcalfeJan MikelsonRuifeng XuCarl Seyla-HammerRaquel Aguiar-IbáñezMayur Amonkar

Published in: Journal of medical economics (2024)

This model demonstrates pembrolizumab provides a valuable new alternative therapy for UK patients with MSH-H/dMMR cancer at the cost of £32,085 per QALY, with confidential discounts anticipated to improve cost-effectiveness further.

Keyphrases

advanced non small cell lung cancer
papillary thyroid
cross sectional
squamous cell
lymph node metastasis
childhood cancer
newly diagnosed